Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -73.75% is 187% below its 5-year average of -25.68%, near the low end of its 5-year range (-73.75%–33.69%).
As of the fiscal period ended Monday, June 30, 2025. 16.98% below its 12-month average of -63.05%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-06-30.
RETURN ON EQUITY (ROE)
-73.75%
RETURN ON EQUITY (ROE) AVG TTM
-63.05%
RETURN ON EQUITY (ROE) AVG 3Y
-54.60%
RETURN ON EQUITY (ROE) AVG 5Y
-25.68%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.98%
CURRENT VS 3Y AVG
-35.08%
CURRENT VS 5Y AVG
-187.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-75.55%
vs the sector median at left
Regencell Bioscience Holdings Limited
Market Cap
$3.85B
Return on Equity (ROE)
-73.75%
TTM Avg
-63.05%
3Y Avg
-54.60%
5Y Avg
-25.68%
Market Cap
$3.96B
Return on Equity (ROE)
1.40%
TTM Avg
-2.98%
3Y Avg
-2.73%
5Y Avg
0.21%
Market Cap
$4.03B
Return on Equity (ROE)
-18.38%
TTM Avg
-15.28%
3Y Avg
-7.60%
5Y Avg
-0.19%
Market Cap
$4.03B
Return on Equity (ROE)
-32.14%
TTM Avg
-46.09%
3Y Avg
-42.05%
5Y Avg
-35.94%
Market Cap
$3.56B
Return on Equity (ROE)
-7.50%
TTM Avg
-76.90%
3Y Avg
-65.24%
5Y Avg
-51.68%
Market Cap
$3.56B
Return on Equity (ROE)
8.25%
TTM Avg
3.56%
3Y Avg
-0.85%
5Y Avg
-3.10%
Market Cap
$4.13B
Return on Equity (ROE)
14.23%
TTM Avg
-7.71%
3Y Avg
-5.30%
5Y Avg
-10.52%
Market Cap
$3.52B
Return on Equity (ROE)
-32.94%
TTM Avg
-45.25%
3Y Avg
-31.88%
5Y Avg
-26.45%
Market Cap
$3.51B
Return on Equity (ROE)
-12.08%
TTM Avg
-47.33%
3Y Avg
-44.55%
5Y Avg
-54.96%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.85B | -73.75% | -63.05% | -54.60% | -25.68% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 1.40% | -2.98% | -2.73% | 0.21% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.03B | -18.38% | -15.28% | -7.60% | -0.19% |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.03B | -32.14% | -46.09% | -42.05% | -35.94% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.56B | -7.50% | -76.90% | -65.24% | -51.68% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 8.25% | 3.56% | -0.85% | -3.10% |
| LivaNova PLC (LIVN)vs › | $4.13B | 14.23% | -7.71% | -5.30% | -10.52% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.52B | -32.94% | -45.25% | -31.88% | -26.45% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.51B | -12.08% | -47.33% | -44.55% | -54.96% |
| Celcuity Inc. (CELC)vs › | $3.49B | N/A | -136.37% | -87.14% | -78.77% |
ROE
-73.8%
ROA
-62.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | -73.75% |
| 2024-06-30 | -52.34% |
| 2023-06-30 | -48.80% |
| 2022-06-30 | -43.50% |
| 2021-06-30 | 33.69% |
| 2020-06-30 | 30.65% |
| 2019-06-30 | 21.27% |
